| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NSCI Stock Overview
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries.
Nanalysis Scientific Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.90 |
| 52 Week High | CA$1.76 |
| 52 Week Low | CA$0.86 |
| Beta | 1.11 |
| 1 Month Change | -26.23% |
| 3 Month Change | -28.00% |
| 1 Year Change | -23.73% |
| 3 Year Change | 116.87% |
| 5 Year Change | n/a |
| Change since IPO | 63.64% |
Recent News & Updates
Shareholder Returns
| NSCI | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 4.7% | 2.0% | -0.8% |
| 1Y | -23.7% | -39.2% | -5.0% |
Return vs Industry: NSCI exceeded the Canadian Medical Equipment industry which returned -38.6% over the past year.
Return vs Market: NSCI underperformed the Canadian Market which returned -4.7% over the past year.
Price Volatility
| NSCI volatility | |
|---|---|
| NSCI Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 11.8% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: NSCI is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NSCI's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 107 | Sean Krakiwsky | https://www.nanalysis.com |
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries. It operates through three segments: Nanalysis, RS2D, and Corporate. The company also offers software module packages; manufactures and sells cutting-edge electronics components for precision analytical instruments; and provides monitoring and supporting services for its NMR technologies.
Nanalysis Scientific Fundamentals Summary
| NSCI fundamental statistics | |
|---|---|
| Market Cap | CA$84.79m |
| Earnings (TTM) | -CA$2.75m |
| Revenue (TTM) | CA$18.32m |
4.6x
P/S Ratio-30.8x
P/E RatioIs NSCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSCI income statement (TTM) | |
|---|---|
| Revenue | CA$18.32m |
| Cost of Revenue | CA$6.86m |
| Gross Profit | CA$11.46m |
| Other Expenses | CA$14.22m |
| Earnings | -CA$2.75m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 62.57% |
| Net Profit Margin | -15.04% |
| Debt/Equity Ratio | 14.1% |
How did NSCI perform over the long term?
See historical performance and comparisonValuation
Is NSCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NSCI?
Other financial metrics that can be useful for relative valuation.
| What is NSCI's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CA$84.79m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.8x |
| Enterprise Value/EBITDA | -55.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NSCI's PS Ratio compare to its peers?
| NSCI PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 315.9x | ||
SQD SQI Diagnostics | 10.3x | n/a | CA$63.0m |
MIR MedMira | 94x | n/a | CA$87.6m |
PINK Perimeter Medical Imaging AI | 1088.2x | 66.1% | CA$115.9m |
TLT Theralase Technologies | 71.1x | 65.6% | CA$61.6m |
NSCI Nanalysis Scientific | 4.6x | 64.9% | CA$84.8m |
Price-To-Sales vs Peers: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (315.9x).
Price to Earnings Ratio vs Industry
How does NSCI's PE Ratio compare vs other companies in the CA Medical Equipment Industry?
Price-To-Sales vs Industry: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the Canadian Medical Equipment industry average (7.2x)
Price to Sales Ratio vs Fair Ratio
What is NSCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.6x |
| Fair PS Ratio | 21.4x |
Price-To-Sales vs Fair Ratio: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (21.4x).
Share Price vs Fair Value
What is the Fair Price of NSCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSCI's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Nanalysis Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
64.9%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NSCI's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if NSCI's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if NSCI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NSCI's revenue (64.9% per year) is forecast to grow faster than the Canadian market (6.5% per year).
High Growth Revenue: NSCI's revenue (64.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NSCI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Nanalysis Scientific performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-49.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSCI is currently unprofitable.
Growing Profit Margin: NSCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSCI is unprofitable, and losses have increased over the past 5 years at a rate of 49.5% per year.
Accelerating Growth: Unable to compare NSCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSCI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).
Return on Equity
High ROE: NSCI has a negative Return on Equity (-5.26%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Nanalysis Scientific's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NSCI's short term assets (CA$33.6M) exceed its short term liabilities (CA$15.0M).
Long Term Liabilities: NSCI's short term assets (CA$33.6M) exceed its long term liabilities (CA$8.8M).
Debt to Equity History and Analysis
Debt Level: NSCI has more cash than its total debt.
Reducing Debt: NSCI's debt to equity ratio has reduced from 34.8% to 14.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NSCI has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 29.7% each year.
Discover healthy companies
Dividend
What is Nanalysis Scientific current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSCI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NSCI has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Sean Krakiwsky (52 yo)
3yrs
Tenure
CA$387,400
Compensation
Mr. Sean Krakiwsky, M.Sc., is Director at QUAD SYSTEMS AG from March 2022. He is a Founder of Nanalysis Scientific Corp. and has been its Chief Executive Officer, President and Director since June 4, 2019...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD299.96K) is above average for companies of similar size in the Canadian market ($USD176.25K).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: NSCI's management team is considered experienced (2.8 years average tenure).
Board Members
Experienced Board: NSCI's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.7%.
Top Shareholders
Company Information
Nanalysis Scientific Corp.'s employee growth, exchange listings and data sources
Key Information
- Name: Nanalysis Scientific Corp.
- Ticker: NSCI
- Exchange: TSXV
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: CA$84.789m
- Shares outstanding: 94.21m
- Website: https://www.nanalysis.com
Number of Employees
Location
- Nanalysis Scientific Corp.
- Bay 1, 4600 5th Street NE
- Calgary
- Alberta
- T2E 7C3
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/01 00:00 |
| End of Day Share Price | 2022/06/30 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.